EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond the Amyloid Hypothesis: Systemic Drivers, CNS-PNS Crosstalk, and the Future of Alzheimer’s Disease Therapeutics

Amador Velázquez de Castro-Bono, Gracia Castro-Luna iD, José Luis Guil-Guerrero iD

International Journal of Molecular Sciences · 02.06.2026 · 27 (11) · 5042

DOI: 10.3390/ijms27115042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.06.2026. Verfasst von Amador Velázquez de Castro-Bono und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Central de la Defensa "Gómez Ulla", 28047 Madrid, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Central Nervous System, Peripheral Nervous System. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is undergoing a profound paradigm shift, transitioning from a localized, monolithic proteinopathy into a complex, multisystem disorder. This critical review synthesizes recent mechanistic, translational, and clinical insights to dismantle the traditional linear amyloid cascade hypothesis. We explore the synergistic interplay between amyloid-β (Aβ) and tau propagation, positioning chronic neuroinflammation, endolysosomal failure, and metabolic starvation—often framed as “Type 3 Diabetes”—as fundamental disease drivers. Crucially, we highlight the emerging biological bridge of CNS-PNS crosstalk, where central neurodegeneration and peripheral neuropathies are linked by systemic immune activation and microbiota–gut–brain axis dysbiosis. The recent validation of disease-modifying therapies (DMTs) confirms Aβ clearance as a viable pharmacological target; however, the marginal clinical gains and severe radiological risks, such as Amyloid-Related Imaging Abnormalities (ARIA), expose the profound limitations of monotherapy. Ultimately, we argue that isolated amyloid clearance is merely an induction phase. The future of AD therapeutics mandates a sequential combination approach—pairing early plaque debulking with lifelong metabolic and neuroimmune maintenance. Supported by scalable fluid biomarkers (e.g., plasma p-tau217) and the expanded ATN(I) framework, the field must embrace proactive precision medicine and inclusive clinical trial designs to successfully transform AD into a manageable chronic condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesCentral Nervous SystemPeripheral Nervous SystemHumansAnimalstau ProteinsBrain

Stichwörter der Autor:innen

Alzheimer’s diseasebrain insulin resistancecognitive declinedisease-modifying therapiesmicrobiota–gut–brain axisneuroinflammationsystemic neurodegeneration

Substanzen

Amyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Hospital Central de la Defensa "Gómez Ulla", 28047 Madrid, Spain.
  • Department of Nursing, Physiotherapy and Medicine, University of Almería, 04120 Almería, Spain.
  • Food Technology Division, University of Almería, 04120 Almería, Spain.

ORCID-Profile: Gracia Castro-Luna, José Luis Guil-Guerrero

Zitieren

APA

Velázquez de Castro-Bono, A., Castro-Luna, G., & Guil-Guerrero, J. L. (2026). Beyond the Amyloid Hypothesis: Systemic Drivers, CNS-PNS Crosstalk, and the Future of Alzheimer’s Disease Therapeutics. International Journal of Molecular Sciences, 27(11), 5042. https://doi.org/10.3390/ijms27115042

Vancouver

Velázquez de Castro-Bono A, Castro-Luna G, Guil-Guerrero JL. Beyond the Amyloid Hypothesis: Systemic Drivers, CNS-PNS Crosstalk, and the Future of Alzheimer’s Disease Therapeutics. International Journal of Molecular Sciences. 2026;27(11):5042. doi:10.3390/ijms27115042

BibTeX
@article{VelzquezdeCastroBono2026,
  author = {Velázquez de Castro-Bono, Amador and Castro-Luna, Gracia and Guil-Guerrero, José Luis},
  title = {Beyond the Amyloid Hypothesis: Systemic Drivers, CNS-PNS Crosstalk, and the Future of Alzheimer’s Disease Therapeutics},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {5042},
  doi = {10.3390/ijms27115042}
}
Kostenlos starten →